Bo Cloud Biomedical Technology(Guangzhou)Co., Ltd.
拨云制药
Bo Cloud Biomedical Technology(Guangzhou)Co., Ltd.
Biotech/Healthcare
Cloudbreak Pharma develops innovative ophthalmic drugs, focusing on small-molecule multi-kinase inhibitor and antibody-small-molecule cooperative conjugation technology platforms for ocular surface diseases, glaucoma, and retinal diseases. Its lead product, CBT-001, has completed a Phase II…
Latest round: Series C (2022)
Source: ChinaBulls — chinabulls.com
Last updated 2022-01-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.